loading

About Author

At BILM, we believe in the power of Educating, Accrediting and inspiring Excellence in Longevity Medicine for doctors in the UK.

Contact Info

0

Your Cart 0

No products in the basket.

 

1. Scope

What is covered:

  • Autologous PRP prepared by centrifugation of a patient’s own whole blood, re-injected locally (intra-articular, intradermal/scalp, peri-tendinous).
  • The uses most relevant to a longevity/preventive clinic: knee osteoarthritis (OA), tendinopathy/soft-tissue, facial skin ageing, and androgenetic alopecia (AGA).
  • Positioning of PRP as adjunctive to conventional primary and secondary care.

What is NOT covered / explicitly out of scope:

  • Systemic “anti-ageing” or intravenous PRP, and “young plasma”/plasma-exchange rejuvenation — there is no robust human evidence that autologous PRP delivered systemically slows biological ageing, reduces mortality, or improves validated ageing biomarkers. Any such use is experimental and should be only in research.
  • Allogeneic platelet products, platelet lysate manufacturing, and PRP as a licensed transfusion product.
  • Dental, ophthalmic, wound-care and gynaecological indications (mentioned only for context).

Regulatory framing (UK): Autologous PRP prepared and re-administered at point of care is generally treated as a clinical procedure rather than a licensed medicinal product; there is no marketing authorisation from the MHRA/EMA for an “anti-ageing” indication. All longevity uses below are off-label / non-licensed and require explicit informed consent.

2. Background and pathophysiology

Biological rationale. PRP is plasma with a platelet concentration above whole blood. On activation (collagen exposure, or added calcium chloride/thrombin), platelet granules release a panel of growth factors — PDGF, TGF-β, VEGF, EGF, bFGF, IGF-1 — plus cytokines and chemokines; roughly 70–95% is released within about 10 minutes, with the remainder over a few days (Finnoff et al., AMSSM Position Statement, Clinical Journal of Sport Medicine, 2021). These mediators are implicated in angiogenesis, fibroblast/tenocyte and chondrocyte activity, matrix synthesis, and modulation of inflammation (Finnoff et al., Clinical Journal of Sport Medicine, 2021).

Mechanisms relevant to ageing. The longevity-relevant hypothesis is that PRP counteracts local tissue-level ageing — cellular senescence, extracellular-matrix degradation, and impaired regenerative capacity — rather than systemic ageing. In degenerative joints the proposed target is chondrocyte senescence and the senescence-associated secretory phenotype (SASP); in skin, dermal fibroblast activity and collagen remodelling; in scalp, prolongation of the anagen (growth) phase. These remain mechanistic hypotheses; none is validated as a clinical anti-ageing endpoint in humans.

Formulation matters. PRP is heterogeneous. Key descriptors are platelet concentration, leukocyte content (leukocyte-rich, LR-PRP vs leukocyte-poor, LP-PRP), red-cell content, and activation method (Finnoff et al., Clinical Journal of Sport Medicine, 2021). These variables materially affect both efficacy and adverse-event rates and are a major source of between-study heterogeneity (Le et al., Current Reviews in Musculoskeletal Medicine, 2018).

Preclinical evidence (clearly separated — hypothesis-generating only, NOT a basis for clinical claims):

  • In a rat knee-OA model and in vitro, PRP suppressed chondrocyte senescence markers (p16, p21, p53), reduced SASP cytokines (IL-1β, IL-6, TNF), improved mitochondrial function and reduced matrix-degrading enzymes (MMP13, ADAMTS5) (Zhang et al., American Journal of Sports Medicine, 2026 — controlled laboratory study).
  • In senescence-accelerated mice, PRP was associated with recovery of stem-cell function and prolonged survival (Liu et al., Biomaterials, 2014).
  • These animal/in-vitro “delayed ageing” signals have not been reproduced as clinical anti-ageing outcomes in humans.

3. Evidence base and grading

Types of evidence available. For local musculoskeletal and dermatological uses there are multiple RCTs and meta-analyses; for knee OA there is a large, well-conducted, fully blinded placebo-controlled RCT (RESTORE; Bennell et al., JAMA, 2021) and a Level 1 meta-analysis of 18 RCTs (Bensa et al., American Journal of Sports Medicine, 2025). There are no RCTs with hard longevity endpoints (mortality, incident multimorbidity, validated epigenetic/biological-age clocks). Outcomes studied are symptomatic and functional (pain VAS, WOMAC/IKDC), structural surrogates (cartilage volume), and cosmetic surrogates (hair density, skin texture).

Certainty-of-evidence and recommendations by outcome:

Indication / outcomeEvidence statementCertainty (GRADE)Strength of recommendation
Knee OA — pain & functionMeta-analysis of 18 RCTs (n≈1,995) found PRP superior to placebo, exceeding the MCID for WOMAC at all timepoints and for VAS pain at 3–6 months, with benefit driven by high-platelet PRP (Bensa et al., American Journal of Sports Medicine, 2025). However, the fully blinded RESTORE RCT (n=288, LP-PRP) found no significant benefit vs saline for pain at 12 months (−2.1 vs −1.8 points; P=.17) (Bennell et al., JAMA, 2021). Inconsistency is substantial.Low (serious inconsistency; heterogeneous formulations; the best-blinded trial negative)Conditional — reasonable to consider as an off-label adjunct in selected patients after conventional measures; be transparent that the best-blinded trial was negative.
Knee OA — structural / disease modificationRESTORE showed no slowing of medial tibial cartilage loss (−1.4% vs −1.2%; P=.81) and no benefit in 29 of 31 secondary outcomes (Bennell et al., JAMA, 2021).Very lowRecommend against claiming disease modification.
Lateral epicondylitis / patellar tendinopathy / plantar fasciitisEvidence-based review reports high-quality support for LR-PRP in lateral epicondylitis and LP-PRP in knee OA, moderate support for LR-PRP in patellar tendinopathy and for PRP in plantar fasciitis (Le et al., Current Reviews in Musculoskeletal Medicine, 2018).Low–Moderate (indication-specific)Conditional — consider off-label as adjunct.
Rotator cuff tendinopathy, hip OA, Achilles tendinopathy, muscle injury, ACL reconstructionInsufficient evidence for rotator cuff tendinopathy, hip OA and high ankle sprains; demonstrated lack of efficacy for Achilles tendinopathy, muscle injury, fracture/nonunion and surgical augmentation (Le et al., Current Reviews in Musculoskeletal Medicine, 2018). A Cochrane review of platelet-rich therapies for soft-tissue injury found low-quality evidence and no clear clinically important benefit (Moraes et al., Cochrane Database of Systematic Reviews, 2014).Very low–LowRecommend against routine use / Only in research.
Facial skin ageingSystematic review (24 studies, 8 RCTs, n=480) found modest, possibly transient improvement in facial texture and fine lines, with adjuvant PRP accelerating healing after fractional laser; improvement typically <50% and durability unknown (Maisel-Campbell et al., Archives of Dermatological Research, 2020). A comprehensive review concurred that most high-quality evidence shows only subtle-to-modest, sometimes conflicting benefit (Bajaj et al., Advances in Therapy, 2022).LowConditional / cosmetic — may offer, off-label, with realistic expectations.
Androgenetic alopecia (hair density)Meta-analysis of 11 RCTs found PRP significantly increased hair number, thickness and density vs placebo (Papakonstantinou et al., Plastic and Reconstructive Surgery, 2023); a separate meta-analysis reported an SMD in hair density of 0.51 vs placebo (Gupta et al., Dermatologic Surgery, 2019). Against minoxidil, PRP showed no clear advantage in hair density but higher patient satisfaction, with high heterogeneity (Umar et al., Aesthetic Plastic Surgery, 2026).LowConditional — may consider off-label, ideally as adjunct to minoxidil/standard therapy.
Systemic anti-ageing / longevity endpointsNo human RCT data. Animal/in-vitro signals only (Liu et al., Biomaterials, 2014; Zhang et al., American Journal of Sports Medicine, 2026).Very lowOnly in research / Recommend against in routine practice.

Cross-cutting limitations: wide variation in PRP preparation and dosing (risk of bias and indirectness) (Le et al., Current Reviews in Musculoskeletal Medicine, 2018); a fully blinded negative trial against positive pooled estimates (inconsistency) (Bennell et al., JAMA, 2021; Bensa et al., American Journal of Sports Medicine, 2025); small samples and non-standardised outcomes for cosmetic endpoints (imprecision) (Maisel-Campbell et al., Archives of Dermatological Research, 2020); and likely publication bias toward positive small studies.

4. Patient selection and indications

Who may benefit (within a longevity clinic, all off-label):

  • Symptomatic mild-to-moderate knee OA (Kellgren–Lawrence 2–3) in adults who have not responded to exercise, weight optimisation and standard analgesia and who wish to defer or avoid corticosteroid/surgery. High-platelet, leukocyte-poor preparations are associated with better and more durable response (Bensa et al., American Journal of Sports Medicine, 2025; Le et al., Current Reviews in Musculoskeletal Medicine, 2018).
  • Chronic recalcitrant tendinopathy (lateral epicondylitis, patellar tendinopathy, plantar fasciitis) failing first-line rehabilitation (Le et al., Current Reviews in Musculoskeletal Medicine, 2018).
  • Aesthetic skin ageing — periorbital fine lines, texture, or as an adjuvant to fractional laser (Maisel-Campbell et al., Archives of Dermatological Research, 2020; Bajaj et al., Advances in Therapy, 2022).
  • Early-to-moderate AGA (both sexes) seeking a treatment additional or alternative to minoxidil/finasteride (Papakonstantinou et al., Plastic and Reconstructive Surgery, 2023; Umar et al., Aesthetic Plastic Surgery, 2026).

Exclusion criteria / high-risk groups (avoid or specialist input):

  • Active local or systemic infection; injection through infected/cellulitic skin.
  • Active malignancy, or premalignant lesions at the treatment site (growth-factor delivery is a theoretical concern — mechanistic caution, no robust human harm data).
  • Significant thrombocytopenia, platelet dysfunction, or coagulopathy; therapeutic anticoagulation (relative).
  • Haemodynamic instability, severe anaemia.
  • Unrealistic expectations, or a request for systemic/IV PRP for “anti-ageing” — decline outside research.

Regulatory and ethical status: All longevity indications are off-label / non-licensed with no MHRA/EMA anti-ageing authorisation. Practice should be framed as adjunctive care with documented informed consent; systemic or disease-modification claims belong within clinical-trial frameworks only.

5. Assessment and baseline work-up

History and examination: target symptom (pain, function, cosmetic concern) with a validated baseline score — e.g. WOMAC/KOOS and pain VAS for knee OA; standardised photography ± trichoscopy/hair-density count for AGA; validated photo-scales for skin ageing. Document analgesic and prior-treatment history, comorbidities, and medications (anticoagulants/antiplatelets, systemic corticosteroids, NSAIDs).

Baseline investigations:

  • FBC (platelet count and haemoglobin — both affect PRP quality and safety) and, where relevant, coagulation screen.
  • For knee OA: weight-bearing radiographs to confirm K–L grade; MRI is not required routinely.
  • For AGA: exclude reversible contributors (ferritin, TSH, and in women androgen screen where clinically indicated).
  • Screen for infection at the intended site.

Risk stratification:

  • Lower risk / more likely to benefit: mild–moderate localised disease, no bleeding risk, high-platelet LP-PRP for joints.
  • Higher risk / less likely to benefit: advanced structural disease, anticoagulated, immunosuppressed, or seeking systemic/structural benefit.

Baseline documentation for meaningful follow-up: the validated outcome score, standardised imaging/photography, and PRP preparation parameters (platelet concentration/fold-increase, leukocyte status, activation method, volume) — because these drive reproducibility and outcome (Le et al., Current Reviews in Musculoskeletal Medicine, 2018; Bensa et al., American Journal of Sports Medicine, 2025). Do not record or rely on “biological-age” biomarkers as efficacy endpoints — the linkage to PRP benefit is unproven.

6. Dosing regimens and practical implementation

There is no single validated protocol; regimens are empirical. Distinguish better-supported from extrapolated schedules.

Knee OA (better-supported human data):

  • 3 intra-articular injections, one week apart is the most commonly studied schedule and the one favoured in guideline appraisal (Bennell et al., JAMA, 2021; AAOS, Management of Osteoarthritis of the Knee [Non-Arthroplasty], 2021).
  • High-platelet, leukocyte-poor PRP is preferred for the knee: high-platelet preparations gave clinically superior, more durable results in meta-analysis (Bensa et al., American Journal of Sports Medicine, 2025), and LP-PRP is supported for knee OA with fewer local adverse effects than LR-PRP (Le et al., Current Reviews in Musculoskeletal Medicine, 2018; Nakagawa et al., PM&R, 2026).
  • Consider re-treatment on symptom recurrence rather than a fixed re-dosing schedule; durability beyond ~12 months is not well established.

Tendinopathy (indication-specific):

  • LR-PRP is favoured for lateral epicondylitis and patellar tendinopathy (Le et al., Current Reviews in Musculoskeletal Medicine, 2018); typically 1–2 peri-/intra-lesional injections under ultrasound guidance. Dose–response is not well defined.

Facial skin ageing (cosmetic, lower-certainty):

  • Intradermal injection, commonly 3 sessions at ~1-month intervals; improvement typically modest (<50%) and of uncertain durability, and may be used as an adjuvant after fractional laser to accelerate recovery (Maisel-Campbell et al., Archives of Dermatological Research, 2020; Bajaj et al., Advances in Therapy, 2022).

Androgenetic alopecia (lower-certainty):

  • Intradermal scalp injection; once monthly ×3 followed by a 3–6-month maintenance period is the schedule recommended in meta-analysis (Gupta et al., Dermatologic Surgery, 2019). Best positioned as an adjunct to minoxidil (Umar et al., Aesthetic Plastic Surgery, 2026).

Regimens requiring caution / not recommended outside research: any systemic/IV PRP, “whole-body rejuvenation” protocols, and fixed indefinite re-dosing schedules — no robust human data (Liu et al., Biomaterials, 2014; Zhang et al., American Journal of Sports Medicine, 2026).

7. Monitoring, safety and follow-up

Overall safety. PRP is autologous and has a favourable safety profile, with no severe adverse events reported across large meta-analyses for knee OA or lateral epicondylitis (Nakagawa et al., PM&R, 2026; Fucaloro et al., Arthroscopy, 2025; Driscoll et al., Arthroscopy, 2026). However, it is not innocuous: for knee OA the overall complication rate was significantly higher than placebo (18.66% vs 9.14%; number needed to harm ≈ 11), though comparable to hyaluronic acid and corticosteroid, and almost all events were mild-to-moderate and self-limiting (Fucaloro et al., Arthroscopy, 2025). Adverse events were reported in ~18.7% of intra-articular PRP knees, most commonly mild pain/swelling (~10.6%) (Nakagawa et al., PM&R, 2026).

Adverse effects:

  • Common (mild, transient): injection-site pain, swelling, stiffness, bruising, itching; significantly more frequent with leukocyte-rich PRP (Nakagawa et al., PM&R, 2026; Driscoll et al., Arthroscopy, 2026). In lateral epicondylitis, injection-site pain occurred in ~13% (NNH ≈ 19), all resolving within the study periods (Driscoll et al., Arthroscopy, 2026).
  • Uncommon: vasovagal reaction, transient flare of joint pain.
  • Rare/serious: procedural local infection. One high-quality knee-OA trial flagged treatment-related hypertension and proteinuria (Common Toxicity Criteria grade ≥3) as a safety signal warranting further evaluation (AAOS, Management of Osteoarthritis of the Knee [Non-Arthroplasty], 2021).

Monitoring plan:

  • Clinical: reassess the validated outcome score (pain/function, photography/hair density) at baseline and follow-up. Advise patients that mild post-procedure pain/swelling is expected, especially with LR-PRP (Nakagawa et al., PM&R, 2026).
  • Laboratory/imaging: no routine post-procedure bloods or imaging are required for local PRP. Repeat imaging only if clinically indicated.
  • Ageing biomarkers: none are validated to track PRP response — do not use to justify continuation.

Suggested timepoints: review at ~1 month (early response/tolerability), 3 and 6 months (peak reported benefit for joints/skin/hair), and 12 months (durability / decision to re-treat).

Actions for abnormal findings: treat suspected septic arthritis/injection-site infection urgently and refer; stop PRP if no meaningful benefit by the expected window; investigate any new hypertension/proteinuria; escalate structural or red-flag joint findings to orthopaedics/rheumatology.

Interactions:

  • Antiplatelets/anticoagulants may reduce PRP quality and increase bruising — review peri-procedure per bleeding risk.
  • Systemic corticosteroids and NSAIDs may theoretically blunt the growth-factor/inflammatory response; timing relative to injection is not standardised (mechanistic caution).
  • Local corticosteroid injection at the same site around the same time is best avoided.

Special populations:

  • Pregnancy/breastfeeding: no safety data for elective/cosmetic PRP — avoid.
  • Renal/hepatic impairment: no specific data; the autologous local procedure is generally low-risk but assess bleeding risk and the reported proteinuria/hypertension signal (AAOS, 2021).
  • Frailty / extremes of age: limited evidence; benefit less certain and consent/goals should be individualised.

8. Contraindications and cautions

Absolute contraindications:

  • Active infection at or near the injection site, or systemic sepsis.
  • Significant thrombocytopenia or platelet dysfunction precluding a usable product.
  • Known hypersensitivity to a required additive (e.g. bovine thrombin, if used).

Relative contraindications / specialist advice advised:

  • Therapeutic anticoagulation or bleeding disorder.
  • Active or recent malignancy (particularly at/near the site) — growth-factor delivery is a theoretical concern (mechanistic plausibility only; no robust human harm data).
  • Immunosuppression; poorly controlled diabetes; severe anaemia.
  • Pregnancy/breastfeeding for elective indications.

Harm likely to outweigh benefit with current evidence:

  • Systemic/IV PRP for longevity or “biological-age reversal” — no evidence of benefit, uncharacterised risk → research only.
  • PRP promoted as disease-modifying/cartilage-regenerating in knee OA — not supported (Bennell et al., JAMA, 2021).
  • Indications with negative evidence (e.g. Achilles tendinopathy, acute muscle injury, routine rotator-cuff/ACL augmentation) (Le et al., Current Reviews in Musculoskeletal Medicine, 2018; Moraes et al., Cochrane Database of Systematic Reviews, 2014).

9. Practical management scenarios

Scenario A — Middle-aged adult with symptomatic knee OA and cardiometabolic risk factors.

  • Recommendation: Consider PRP as an off-label adjunct (Conditional) after optimising exercise, weight and standard analgesia — not as first-line and not as disease-modifying.
  • Assessment: confirm K–L 2–3 on radiograph; baseline WOMAC + pain VAS; FBC; review antiplatelet/anticoagulant use; address cardiometabolic risk in parallel (the higher-value longevity intervention).
  • Shared decision-making/consent: explain off-label status, modest and inconsistent evidence (the best-blinded RCT was negative — Bennell et al., JAMA, 2021), NNH ≈ 11 for mostly mild adverse events (Fucaloro et al., Arthroscopy, 2025), and out-of-pocket cost.
  • Initiation: high-platelet, leukocyte-poor PRP; 3 intra-articular injections one week apart (Bensa et al., American Journal of Sports Medicine, 2025; AAOS, 2021).
  • Monitoring/follow-up: review at 1, 3, 6 and 12 months with repeat WOMAC/VAS.
  • Escalate/stop: no meaningful improvement by 3 months → stop; progressive structural disease → orthopaedic referral.

Scenario B — Older, frail patient with multimorbidity considering PRP for knee OA.

  • Recommendation: generally avoid or restrict; consider only highly selectively (weak/against). Frailty populations are under-represented in trials (indirectness) and periprocedural/bleeding risk is higher.
  • Assessment: medication review (anticoagulants, corticosteroids), bleeding and infection risk, goals of care.
  • Shared decision-making: emphasise limited evidence in frailty and prioritise conservative measures (analgesia, physiotherapy, falls/bone-health optimisation).
  • If proceeding: LP-PRP to minimise local reaction (Nakagawa et al., PM&R, 2026); single course; low threshold to stop.
  • Escalate/stop: any infection, uncontrolled hypertension/new proteinuria (AAOS, 2021), or lack of benefit.

Scenario C — PRP as an adjunct in a patient already under specialist care (e.g. tendinopathy under sports medicine, or AGA under dermatology).

  • Recommendation: Consider as an adjunct (Conditional), coordinated with the specialist.
  • Assessment: confirm diagnosis and that first-line therapy is optimised (rehabilitation for tendinopathy — Le et al., Current Reviews in Musculoskeletal Medicine, 2018; minoxidil ± finasteride for AGA — Umar et al., Aesthetic Plastic Surgery, 2026); baseline validated score/photography.
  • Consent: off-label adjunctive status; realistic, modest expected effect; possible non-response.
  • Initiation: indication-specific formulation (LR-PRP for lateral epicondylitis/patellar tendinopathy — Le et al., 2018); scalp series monthly ×3 then maintenance for AGA (Gupta et al., Dermatologic Surgery, 2019).
  • Monitoring/follow-up: 3- and 6-month objective reassessment; continue only if measurable benefit.
  • Escalate/refer: communicate outcomes to the specialist; stop if no benefit.

10. Research gaps and future directions

  • No hard longevity endpoints. There are no RCTs linking PRP to mortality, incident multimorbidity, functional trajectory, or validated biological-age measures. Systemic/anti-ageing use should remain research only (Liu et al., Biomaterials, 2014; Zhang et al., American Journal of Sports Medicine, 2026).
  • Standardisation. Lack of harmonised reporting of platelet dose, leukocyte content, and activation is the dominant source of heterogeneity and non-reproducibility (Le et al., Current Reviews in Musculoskeletal Medicine, 2018; Bensa et al., American Journal of Sports Medicine, 2025); adoption of a standard classification is a priority.
  • Reconciling discordant knee-OA data. The gap between the positive pooled estimate (Bensa et al., American Journal of Sports Medicine, 2025) and the negative, rigorously blinded RESTORE trial (Bennell et al., JAMA, 2021) needs resolution via large, blinded, high-platelet-defined RCTs with pre-registered structural and patient-important endpoints.
  • Durability and re-treatment intervals are undefined across joint, skin and scalp uses (Maisel-Campbell et al., Archives of Dermatological Research, 2020; Gupta et al., Dermatologic Surgery, 2019).
  • Surrogate-to-outcome linkage. Whether improvements in hair density, skin texture, or synovial cytokines translate into durable, patient-important benefit is unproven — avoid inferring hard benefit from surrogates.
  • Safety signal follow-up. The single-trial hypertension/proteinuria signal for intra-articular PRP warrants dedicated pharmacovigilance (AAOS, Management of Osteoarthritis of the Knee [Non-Arthroplasty], 2021).
  • Preferred posture: deliver PRP for longevity indications within well-designed trials or prospective registries capturing preparation parameters and long-term outcomes.

 

References

  1. The Use of Platelet‐Rich Plasma for the Treatment of Osteonecrosis of the Femoral Head: A Systematic Review. Han J, Gao F, Li Y, et al. BioMed Research International. 2020;2020:2642439. doi:10.1155/2020/2642439.
  2. Assessment of Adverse Events and Safety Associated With Intra-Articular Platelet-Rich Plasma Injections Compared to Other Injectates for Knee Osteoarthritis: A Systematic Review and Meta-Analysis. Nakagawa HF, Kim J, Rabinowitz J, Sussman WI. PM & R : The Journal of Injury, Function, and Rehabilitation. 2026;. doi:10.1002/pmrj.70141.
  3. Complications of Platelet-Rich Plasma Injection for Knee Osteoarthritis Are Similar to Those of Corticosteroids and Hyaluronic Acid but Are Significantly Greater Than Those of Placebo Injections: A Meta-Analysis of Randomized Controlled Trials. Fucaloro SP, Bragg J, Berhane M, et al. Arthroscopy : The Journal of Arthroscopic & Related Surgery : Official Publication of the Arthroscopy Association of North America and the International Arthroscopy Association. 2025;:S0749-8063(25)00373-1. doi:10.1016/j.arthro.2025.05.018.
  4. Effects of Platelet-Rich Plasma on Chondrocyte Senescence and Knee Osteoarthritis Progression. Zhang JY, Xiang XN, Wang XX, et al. The American Journal of Sports Medicine. 2026;54(4):831-847. doi:10.1177/03635465251408090.
  5. Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis. Bennell KL, Paterson KL, Metcalf BR, et al. JAMA. 2021;326(20):2021-2030. doi:10.1001/jama.2021.19415.
  6. PRP Injections for the Treatment of Knee Osteoarthritis: The Improvement Is Clinically Significant and Influenced by Platelet Concentration: A Meta-Analysis of Randomized Controlled Trials. Bensa A, Previtali D, Sangiorgio A, et al. The American Journal of Sports Medicine. 2025;53(3):745-754. doi:10.1177/03635465241246524.
  7. A Systematic Review of the Safety and Effectiveness of Platelet-Rich Plasma (PRP) for Skin Aging. Maisel-Campbell AL, Ismail A, Reynolds KA, et al. Archives of Dermatological Research. 2020;312(5):301-315. doi:10.1007/s00403-019-01999-6.
  8. Preparation and Utility of Platelet-Rich Plasma (PRP) for Facial Aging: A Comprehensive Review. Bajaj S, Orbuch D, Wang JV, Geronemus RG. Advances in Therapy. 2022;39(9):4021-4036. doi:10.1007/s12325-022-02239-6.
  9. Autologous Platelet-Rich Plasma Treatment for Androgenic Alopecia: A Systematic Review and Meta-Analysis of Clinical Trials. Papakonstantinou M, Siotos C, Gasteratos KC, Spyropoulou GA, Gentile P. Plastic and Reconstructive Surgery. 2023;151(5):739e-747e. doi:10.1097/PRS.0000000000010076.
  10. Platelet-Rich Plasma as a Treatment for Androgenetic Alopecia. Gupta AK, Cole J, Deutsch DP, et al. Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]. 2019;45(10):1262-1273. doi:10.1097/DSS.0000000000001894.
  11. Comparative Efficacy and Safety of Platelet Rich Plasma (PRP) Versus Topical Minoxidil for Androgenetic Alopecia: A Systematic Review and Meta-Analysis. Umar M, Anwar A, Shamim L, et al. Aesthetic Plastic Surgery. 2026;50(3):1340-1353. doi:10.1007/s00266-025-05394-7.
  12. Complications of Platelet-Rich Plasma Injections for Lateral Epicondylitis Occur at Comparable Rates to Those of Corticosteroid and Saline Injections: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Driscoll AM, Fucaloro SP, Mulvey M, et al. Arthroscopy : The Journal of Arthroscopic & Related Surgery : Official Publication of the Arthroscopy Association of North America and the International Arthroscopy Association. 2026;42(5):935-946. doi:10.1002/arj.70162.
  13. American Medical Society for Sports Medicine Position Statement: Principles for the Responsible Use of Regenerative Medicine in Sports Medicine. Finnoff JT, Awan TM, Borg-Stein J, et al. Clinical Journal of Sport Medicine : Official Journal of the Canadian Academy of Sport Medicine. 2021;31(6):530-541. doi:10.1097/JSM.0000000000000973.
  14. Management of Osteoarthritis of the Knee (Non-Arthroplasty): Evidence-Based Clinical Practice Guideline. American Academy of Orthopaedic Surgeons (2021).
  15. Current Clinical Recommendations for Use of Platelet-Rich Plasma. Le ADK, Enweze L, DeBaun MR, Dragoo JL. Current Reviews in Musculoskeletal Medicine. 2018;11(4):624-634. doi:10.1007/s12178-018-9527-7.
  16. Delayed Animal Aging Through the Recovery of Stem Cell Senescence by Platelet Rich Plasma. Liu HY, Huang CF, Lin TC, et al. Biomaterials. 2014;35(37):9767-9776. doi:10.1016/j.biomaterials.2014.08.034.